title: Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
abstract: The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?
authors.affiliation: School of Pharmacy, Philadelphia College of Osteopathic Medicine (PCOM), Suwanee, GA, USA.
authors.forename: Brent L
authors.initials: BL
authors.lastname: Rollins
mesh_terms: D000329:Advertising; D000067088:Direct-to-Consumer Advertising; D006801:Humans; D055553:Prescription Drugs; D011642:Publications; D014486:United States Food and Drug Administration
chemical_list: D055553:Prescription Drugs
keywords: Direct-to-Consumer Advertising (DTCA); Fair Balance; Food and Drug Administration (FDA); Notice of Violations (NOV); Office of Prescription Drug Promotion (OPDP)